Cargando…
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
INTRODUCTION: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone in patients with CKD and type 2 diabetes (T2D). This analysis explores the impact of use...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720648/ https://www.ncbi.nlm.nih.gov/pubmed/35005312 http://dx.doi.org/10.1016/j.ekir.2021.10.008 |
_version_ | 1784625167678308352 |
---|---|
author | Rossing, Peter Filippatos, Gerasimos Agarwal, Rajiv Anker, Stefan D. Pitt, Bertram Ruilope, Luis M. Chan, Juliana C.N. Kooy, Adriaan McCafferty, Kieran Schernthaner, Guntram Wanner, Christoph Joseph, Amer Scheerer, Markus F. Scott, Charlie Bakris, George L. |
author_facet | Rossing, Peter Filippatos, Gerasimos Agarwal, Rajiv Anker, Stefan D. Pitt, Bertram Ruilope, Luis M. Chan, Juliana C.N. Kooy, Adriaan McCafferty, Kieran Schernthaner, Guntram Wanner, Christoph Joseph, Amer Scheerer, Markus F. Scott, Charlie Bakris, George L. |
author_sort | Rossing, Peter |
collection | PubMed |
description | INTRODUCTION: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone in patients with CKD and type 2 diabetes (T2D). This analysis explores the impact of use of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) on the treatment effect of finerenone. METHODS: Patients (N = 5674) with T2D, urine albumin-to-creatinine ratio (UACR) of 30 to 5000 mg/g and estimated glomerular filtration rate (eGFR) of 25 to <75 ml/min per 1.73 m(2) receiving optimized renin-angiotensin system (RAS) blockade were randomized to finerenone or placebo. Endpoints were change in UACR and a composite kidney outcome (time to kidney failure, sustained decrease in eGFR ≥40% from baseline, or renal death) and key secondary cardiovascular outcomes (time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) (ClinicalTrials.gov, NCT02540993). RESULTS: Of 5674 patients, 259 (4.6%) received an SGLT-2i at baseline. Reduction in UACR with finerenone was found with or without use of SGLT-2i at baseline, with ratio of least-squares means of 0.69 (95% CI = 0.66–0.71) and 0.75 (95% CI -= 0.62–0.90), respectively (P(interaction) = 0.31). Finerenone also significantly reduced the kidney and key secondary cardiovascular outcomes versus placebo; there was no clear difference in the results by SGLT-2i use at baseline (P(interaction) = 0.21 and 0.46, respectively) or at any time during the trial. Safety was balanced with or without SGLT-2i use at baseline, with fewer hyperkalemia events with finerenone in the SGLT-2i group (8.1% vs. 18.7% without). CONCLUSION: UACR improvement was observed with finerenone in patients with CKD and T2D already receiving SGLT-2is at baseline, and benefits on kidney and cardiovascular outcomes appear consistent irrespective of use of SGLT-2i. |
format | Online Article Text |
id | pubmed-8720648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-87206482022-01-07 Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy Rossing, Peter Filippatos, Gerasimos Agarwal, Rajiv Anker, Stefan D. Pitt, Bertram Ruilope, Luis M. Chan, Juliana C.N. Kooy, Adriaan McCafferty, Kieran Schernthaner, Guntram Wanner, Christoph Joseph, Amer Scheerer, Markus F. Scott, Charlie Bakris, George L. Kidney Int Rep Clinical Research INTRODUCTION: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone in patients with CKD and type 2 diabetes (T2D). This analysis explores the impact of use of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) on the treatment effect of finerenone. METHODS: Patients (N = 5674) with T2D, urine albumin-to-creatinine ratio (UACR) of 30 to 5000 mg/g and estimated glomerular filtration rate (eGFR) of 25 to <75 ml/min per 1.73 m(2) receiving optimized renin-angiotensin system (RAS) blockade were randomized to finerenone or placebo. Endpoints were change in UACR and a composite kidney outcome (time to kidney failure, sustained decrease in eGFR ≥40% from baseline, or renal death) and key secondary cardiovascular outcomes (time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) (ClinicalTrials.gov, NCT02540993). RESULTS: Of 5674 patients, 259 (4.6%) received an SGLT-2i at baseline. Reduction in UACR with finerenone was found with or without use of SGLT-2i at baseline, with ratio of least-squares means of 0.69 (95% CI = 0.66–0.71) and 0.75 (95% CI -= 0.62–0.90), respectively (P(interaction) = 0.31). Finerenone also significantly reduced the kidney and key secondary cardiovascular outcomes versus placebo; there was no clear difference in the results by SGLT-2i use at baseline (P(interaction) = 0.21 and 0.46, respectively) or at any time during the trial. Safety was balanced with or without SGLT-2i use at baseline, with fewer hyperkalemia events with finerenone in the SGLT-2i group (8.1% vs. 18.7% without). CONCLUSION: UACR improvement was observed with finerenone in patients with CKD and T2D already receiving SGLT-2is at baseline, and benefits on kidney and cardiovascular outcomes appear consistent irrespective of use of SGLT-2i. Elsevier 2021-10-14 /pmc/articles/PMC8720648/ /pubmed/35005312 http://dx.doi.org/10.1016/j.ekir.2021.10.008 Text en © 2021 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Clinical Research Rossing, Peter Filippatos, Gerasimos Agarwal, Rajiv Anker, Stefan D. Pitt, Bertram Ruilope, Luis M. Chan, Juliana C.N. Kooy, Adriaan McCafferty, Kieran Schernthaner, Guntram Wanner, Christoph Joseph, Amer Scheerer, Markus F. Scott, Charlie Bakris, George L. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy |
title | Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy |
title_full | Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy |
title_fullStr | Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy |
title_full_unstemmed | Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy |
title_short | Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy |
title_sort | finerenone in predominantly advanced ckd and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720648/ https://www.ncbi.nlm.nih.gov/pubmed/35005312 http://dx.doi.org/10.1016/j.ekir.2021.10.008 |
work_keys_str_mv | AT rossingpeter finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT filippatosgerasimos finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT agarwalrajiv finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT ankerstefand finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT pittbertram finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT ruilopeluism finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT chanjulianacn finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT kooyadriaan finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT mccaffertykieran finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT schernthanerguntram finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT wannerchristoph finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT josephamer finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT scheerermarkusf finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT scottcharlie finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT bakrisgeorgel finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy AT finerenoneinpredominantlyadvancedckdandtype2diabeteswithorwithoutsodiumglucosecotransporter2inhibitortherapy |